Can a trial carried out in China back a US approval? Investors in anti-PD-(L)1 players will find out soon enough.
Astrazeneca’s Himalaya study is a surprising hit in first-line liver cancer, but competition is already present.
Trodelvy has a chance to score in a study designed to expand its use, but given Gilead’s R&D track record nothing is certain.
Cstone/EQRX and Shanghai Junshi/Coherus might have approvable anti-PD-(L)1 projects, but can Keytruda be challenged on price?
The first of 2021’s eight remaining oncology meetings kicks off next week. Here’s what to look out for.
The Junshi/Coherus drug only beat chemotherapy, and its study was run not in the US but in China.
Retifanlimab gets knocked back by a US adcom. Could a rival now beat it to become the eighth anti-PD-(L)1 to reach the US market?